New hope for advanced breast cancer: experimental combo enters final testing
NCT ID NCT06680921
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be randomly assigned to receive either the new combination or a doctor's choice of standard therapy. The main goal is to see if the new combination delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIM0270 (an experimental drug) combined with everolimus
- What this could lead to
- If successful, this could offer a new treatment option for people with ER+/HER2- advanced breast cancer whose disease has progressed after CDK4/6 inhibitor therapy.
- What could go wrong
- This is a Phase 3 trial, but the experimental combination may not improve progression-free survival or overall survival compared to standard treatments. Side effects from the combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
-
Anyang Tumor Hospital
Anyang, Henan, China
-
Baoji Central Hospital
Baoji, Shan'Xi, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Binzhou Medical University Hospital
Binzhou, Shandong, China
-
First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
-
First Hospital Of Qinhuangdao
Qinhuangdao, Hebei, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Fujian Provincial Hospital
Fuzhou, Fujian, China
-
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
-
Guangdong Maternal and Child Health Hospital
Guangzhou, Guangdong, China
-
Guangxi Medical University Cancer hospital
Nanning, Guangxi, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
-
Linyi Cancer Hospital
Linyi, Shandong, China
-
Linyi People'S Hostipal
Linyi, Shandong, China
-
Maanshan People's Hospital
Maanshan, Anhui, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
-
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
-
Shandong First Medical University and Shandong Academy of Medical Sciences
Jinan, Shandong, China
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
-
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
Zhengzhou, Henan, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
-
The Central Hospital of Yongzhou
Yongzhou, Hunan, China
-
The First Affiliated Hispital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hispital of Bengbu Medical University
Bengbu, Anhui, China
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of JINZHOU Medical University
Jinzhou, Liaoning, China
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
The First Medical Center of PLA Ggeneral Hospital
Beijing, Beijing Municipality, China
-
The First PEOPLE'S HOSPITAL OF CHANGDE CITY
Changde, Hunan, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
-
Weifang People'S Hospital
Weifang, Shandong, China
-
Weihai Municipal Hospital
Weihai, Shandong, China
-
Wuhan University Zhongnan Hospital
Wuhan, Hubei, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, China
-
Xiangyang Central Hospital
Xiangyang, Hubei, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
-
Zhongshan City People's Hospital
Zhongshan, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug YL202 targets Hard-to-Treat breast cancers
- Simple gloves and socks may shield breast cancer patients from chemo nerve pain
- New hope for advanced breast cancer: YL202 takes on standard treatments in major trial
- New drug shows promise in slowing advanced breast cancer with ESR1 mutation
- New hope for Drug-Resistant breast cancer: phase 3 trial launches
- New hope for advanced breast cancer: drug combo targets resistant tumors